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INTRODUCTION
Dendritic cells (DC) are antigen-presenting cells (APC) that 
play a crucial role in both innate and adaptive immunity, and 
provide antigen to T cells to induce immune responses. DC 
subsets include conventional and plasmacytoid DC. Conven-
tional DC can also be divided into a number of subsets accord-
ing to their localization. Myeloid dendritic cells (mDC)—a typi-
cal conventional DC subtype—can be differentiated in vitro in 
the presence of GM-CSF and are usually CD11c+CD11b+B220 
cells.
Plasmacytoid dendritic cells (pDC, also known as interferon-
producing cells [IPC]), another subset of DC, possess TLR9 re-
ceptors and can be differentiated from bone marrow-derived 
cells in the presence of Flt3 ligand. When stimulated with im-
munostimulatory sequences (ISS, TLR9 agonist), pDC secrete 
abundant type 1 interferon, producing anti-viral immunity.
It is well known that mDC play a major role in antigen presen-
tation and in priming T cells. mDC are professional APC and 
mDC pulsed with ovalbumin (OVA) can induce asthma in the 
mouse model by playing a central role in orchestrating the asth-
matic reaction. However, the effect of pDC on induction of 
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asthma has not been studied extensively.
Asthma is a chronic airway disorder characterized by revers-
ible airway obstruction, airway hyperresponsiveness, and cel-
lular inflammation, predominantly eosinophils and allergen-
specific Th2 lymphocytes.
1,2 Th2 cells are the principal effector 
cells that coordinate many of the actions of other inflammatory 
cells in the airway by the release of cytokines and chemokines.
3-5 
We have shown that ISS inhibits allergic asthmatic reactions via 
various immune mechanisms, and investigations into clinical 
applications are underway.
6 Here, we treated DC with ISS to as-
sess the effect of ISS on asthma induction, and determined the 
effect of administering ISS to mice on pulmonary DC migration. 
We also evaluated the induction of allergic asthmatic reactions 
by mDC and pDC and the in vivo effect of ISS on DC migration 
to the lung.
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Purpose:  To determine the role of plasmacytoid dendritic cells (pDC) and myeloid dendritic cells (mDC) in priming effector T cells to induce allergy, 
and to evaluate the effect of immunostimulatory sequences (ISS, TLR9 agonist) on dendritic cells.  Methods:  Cultured mDC and pDC with/without 
ISS were injected intratracheally into sensitized Balb/C mice. Mice were sacrificed, and then pulmonary function tests, bronchoalveolar lavage (BAL), 
cell counts, and cytokine levels were evaluated. Migration of dendritic cells was also evaluated after ISS administration.  Results:  In mice injected 
with mDC, airway hyperresponsiveness, eosinophil counts, and Th2 cytokine levels in BAL increased with increasing numbers of mDC injected. How-
ever, in mice injected with pDC, none of these changed, suggesting poor priming of T cells by pDC. In addition, mDC pulsed with ISS inhibited asth-
matic reactions, and ISS administration inhibited migration of DC to the lung.  Conclusions:  We suggest that pDC played a limited role in priming 
T cells in this asthma model and that mDC played a major role in inducing asthma. In addition, ISS inhibited migration of DC to the lung.
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MATERIALS AND METHODS
Animals
Balb/c mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME, USA). All animal procedures followed the Uni-
versity of California, San Diego, animal-care guidelines. All ex-
periments were performed in at least triplicate.
Reagents
ISS-ODN (5′-TGACTGTGAACGTTCGAGATGA-3′) was pur-
chased from Trilink Biotechnologies (San Diego, CA, USA). OVA 
was purchased from Sigma-Aldrich (Saint Louis, MS, USA).
Culture of myeloid DC and plasmacytoid DC and isolation of 
pulmonary CD11c+ DC
Myeloid bone marrow-derived dendritic cells (BMDC) were 
prepared from Balb/c mice as described previously.
7 Briefly, 
bone marrow from the femurs and tibias of Balb/c mice was 
plated in petri dishes (Fisher Scientific, Pittsburgh, PA, USA) on 
day 0 at 2×10
5 cells/mL in DC medium, which consisted of 
RPMI (Irvine Scientific, Irvine, CA, USA) supplemented with 
10% heat-inactivated FCS (Life Technologies, Gaithersburg, 
MD, USA), 2 mM L-glutamine (Cellgro, Natham, VA, USA), and 
100 U/mL penicillin/100 µg/mL streptomycin (Pen/Strep; Cell-
gro) containing 5 ng/mL recombinant murine GM-CSF (BD 
PharMingen, San Hose, CA, USA). On day 3, an equal volume 
of DC medium was added. On day 6, one-half of the volume of 
DC medium was replaced. Non-adherent cells were harvested 
on day 7. For plasmacytoid dendritic cells, bone marrow from 
the femurs and tibias of Balb/c mice was plated in petri dishes 
(Fisher Scientific, Pittsburgh, PA, USA) on day 0 at 1.5×10
6 
cells/mL in DC medium containing 5 ng/mL recombinant hu-
man Flt3 ligand (Peprotech, Rocky Hill, NJ, USA). Non-adher-
ent cells were harvested on day 14. Further purification of pDC 
cells using anti-CD11c magnetic beads, B220 magnetic beads, 
and an MACS column (Miltenyi Biotec, Auburn, CA, USA) as 
per the manufacturer’s instructions was performed for selected 
studies. Flow cytometry, after staining with Abs against the fol-
lowing cell surface markers or appropriate isotype controls (BD 
PharMingen), was conducted to characterize the cultured cells: 
CD11c (clone HL3), CD11b (clone M1/70), and B220 (clone 
RA3-6B2). Single-cell lung suspensions were prepared by colla-
genase digestion as described previously.
8 The DC population 
was initially enriched by discontinuous density gradient cen-
trifugation using OptiPrep (Axis-Shield PoC AS, Oslo, Norway) 
according to the manufacturer’s instructions. Low-density cells 
at the interface were harvested, and CD11c+ cells were positive-
ly isolated using anti-CD11c magnetic beads (Miltenyi Biotec 
Inc., Auburn, CA, USA). The CD11c+ population comprised 
greater than 90% of the total cells as determined by FACS analy-
sis. High-density cells were collected and served as a CD11c– 
cell population.
Experimental asthma
Airway inflammation was induced according to a protocol 
previously described with minor modifications.
9 In brief, Balb/
c mice were sensitized by subcutaneous injection of 20 μg OVA 
absorbed with 500 μg alum (Alhydrogel; Brenntag Biosector AS, 
Federikssund, Denmark) per mouse in saline on days 0, 7, and 
14. On days 20 and 25, mice were challenged intratracheally 
with 10
6 DC pulsed with or without OVA (Figs. 1A, 2A) or intra-
nasally with 5 μg OVA (Fig. 3A). Mice were then sacrificed on 
day 26.
To evaluate the role of mDC, mice were divide into groups 
(n=3) and 10
5, 3×10
5, or 10
6 mDC pulsed with OVA were in-
stilled intratracheally (Fig. 1A). Next, mice were divided into six 
groups to evaluate the roles of mDC and pDC with or without 
ISS. mDC alone (group 1), mDC pulsed with OVA (group 2), 
mDC pulsed with OVA and ISS (group 3), pDC alone (group 4), 
pDC pulsed with OVA (group 5), or pDC pulsed with OVA and 
ISS (group 6) were administered intratracheally on days 20 and 
25. One million pDC or mDC were administered to each mouse 
(Fig. 2A). mDC and pDC were pulsed with Ova and/or ISS for 
30 min and were washed thoroughly before instillation.
In the final experiment, mice were divided into four groups: 
group 1 (control, no sensitization), group 2 (sensitization with 
OVA and alum, PBS challenge), group 3 (sensitization with OVA 
and alum, OVA challenge, no treatment), and group 4 (sensiti-
zation with OVA and alum, OVA challenge, ISS treatment). Af-
ter sensitization with OVA and alum, ISS-ODN (50 μg/mouse) 
was administered intraperitoneally 1 day before OVA challenge 
(day 19).
Twenty-four hours after the last challenge (day 26), mice were 
subjected to airway responsiveness tests and then sacrificed by 
CO2 asphyxiation. Five mice were used in each group, and mea-
surements were taken in triplicate.
After sacrifice, bronchoalveolar lavage (BAL) cells and lungs 
were harvested from each mouse. The total number of cells in 
BAL was counted, and BAL cells were stained with Wright-Gi-
emsa stain for the differential count. Percentages of eosinophils 
were determined microscopically using standard morphologi-
cal criteria.
10 The total number of eosinophils was calculated 
from the total cell number and the percentage of eosinophils in 
the differential cell count. The levels of each cytokine (IL-4, IL-
5, IFN-γ) in BAL fluid were determined by ELISA (BD Biosci-
ences - Pharmingen, San Diego, CA, USA).
Airway responsiveness to methacholine (MCh) was assessed 
24 hours after the final OVA challenge using a single-chamber, 
whole-body plethysmograph obtained from Buxco Electronics 
Inc. (Wilmington, NC, USA), as described previously.
9 The Penh, 
a dimensionless value, which correlates well with pulmonary 
resistance measured by conventional two-chamber plethys-
mography in ventilated mice, was used to monitor airway re-
sponsiveness. In the plethysmograph, mice were exposed for 3 
minutes to nebulized PBS to establish baseline Penh values and Plasmacytoid and Myeloid Dendritic Cells in Asthma
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were subsequently exposed to increasing concentrations of 
nebulized MCh (Sigma-Aldrich) in PBS using an Aerosonic ul-
trasonic nebulizer (DeVilbiss Health Care Inc., Somerset, PA, 
USA). Following each nebulization, recordings were taken for 3 
minutes. The Penh values measured during each 3-minute se-
quence were averaged and are expressed for each MCh con-
centration as the percentage of baseline Penh values following 
PBS exposure.
FACS analysis
Cells obtained from the lung were stained for CD11c, CD11b, 
and B220 (BD Biosciences - Pharmingen) and then analyzed 
using a FACSCalibur flow cytometer (BD Biosciences - Immu-
nocytometry Systems, San Jose, CA, USA).
Statistics
Data were compared using the Student’s t-test, and repeated 
measures ANOVA was used to compare plethysmography data. 
A P value of less than or equal to 0.05 was considered statistical-
ly significant.
RESULTS
mDC induce asthma in an mDC number-dependent manner
To elucidate the effect of mDC on asthma induction, 10
5, 3×
10
5, or 10
6 mDC pulsed with OVA were administered intratra-
cheally (Fig. 1A). mDC induced airway hyperresponsiveness in 
an mDC number-dependent manner; the difference between 
groups was statistically significant (P=0.002; Fig. 1B). Eosino-
phil counts in BAL fluid increased significantly with increasing 
numbers of mDC (each P<0.05; Fig. 1C). Th2 cytokine (IL-4 and 
IL-5) levels in BAL also increased significantly and interferon-γ 
decreased, with increasing mDC administration (Fig. 1D).
Isolation of plasmacytoid DC and the effect of pDC on asthma 
induction
To evaluate the effect of pDC on asthma, mDC or pDC (10
6) 
with or without OVA were administered intratracheally after 
sensitization of mice with OVA and alum. To assess the effect of 
ISS on DC, mDC and pDC were also incubated with ISS prior to 
intratracheal administration (groups 3 and 6). The experimen-
Fig. 1.  Myeloid dendritic cells (DC) induced an asthmatic reaction in myeloid dendritic cells (mDC) in a number-dependent manner. (A) Schematic illustration of the 
experimental protocol. Different numbers of myeloid DC were administered intratracheally to Balb/c mice after ovalbumin/alum sensitization. Five mice were used 
in each group and this experiment was performed in triplicate. (B) Airway hyperresponsiveness to methacholine was evaluated. mDC increased airway hyperrespon-
siveness in a number-dependent manner. (C) Eosinophil counts in bronchoalveolar lavage (BAL) fluid also depended on the number of mDC administered. (D) IL-4 and 
IL-5 levels increased with increasing numbers of mDC in BAL fluid. Interferon-γ decreased in group 3. Gp, group; IFN- γ, interferon-γ; MCh: methacholine.
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tal protocol is illustrated in Fig. 2A. pDC were isolated using an-
ti-CD11c and anti-B220 MACS beads, and CD11c+ and B220+ 
groups were isolated with a purity of 94.4% (Fig. 2B). Airway hy-
perresponsiveness and eosinophil counts induced by mDC 
(group 2) were abolished with mDC pulsed with ISS adminis-
tration (group 3; P=0.01 and P<0.001, respectively; Fig. 2C, D). 
Th2 cytokine levels also significantly decreased in the ISS-pulsed, 
mDC-administered group (all P<0.01). However, in the pDC-
administered groups (groups 4, 5, and 6), airway hyperrespon-
siveness and eosinophil counts did not differ from those of the 
non-OVA-pulsed mDC-administered group (group 1), suggest-
ing that priming of T cells by pDC with OVA antigen is poor. 
IL-4 and IL-5 levels were not significantly different compared to 
group 1 (all P>0.05).
In vivo effect of ISS on dendritic cell migration
We also evaluated the in vivo effect of ISS on pulmonary DC 
populations. ISS was administered to mice on day 19 (Fig. 3A) 
and the DC population was counted using flow cytometry. The 
CD11c+CD11b+ cell count increased from 1.84% to 15.80% af-
ter OVA challenge and decreased to 9.02% in the ISS-adminis-
tration group, showing that ISS inhibited migration of mDC 
populations to the lungs. The proportion of CD11c+B220+ cells 
increased from 0.60% to 1.08% after OVA challenge, and de-
creased to 0.69% after ISS administration. In addition, ISS also 
significantly decreased eosinophil counts and Th2 cytokine (IL-
Fig. 2.  Isolation of plasmacytoid dendritic cells (DC) and the effect of plasmacytoid dendritic cells (pDC) with or without an immunostimulatory sequence (ISS) on 
asthma induction. (A) Schematic illustration of the experimental protocol. Myeloid dendritic cells (mDC) or pDC (106) with or without ISS stimulation were adminis-
tered intratracheally to Balb/c mice after ovalbumin (OVA)/alum sensitization. Five mice were used in each group and this experiment was performed in duplicate. (B) 
Characterization of pDC subsets after isolation using anti-CD11c and anti-B220 MACS antibodies. Isolated cells exhibited 94.4% purity. (C, D) Airway hyperrespon-
siveness curve showing that pDC with or without OVA pulsing did not induce airway hyperresponsiveness compared to mDC without OVA (P>0.05). mDC pulsed 
with OVA increased airway hyperresponsiveness, eosinophil counts, and IL-4 and IL-5 levels in BAL, the effect of which was abolished by administration of mDC 
pulsed with ISS and OVA.
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4 and IL-5) levels in the lungs (all P<0.01; Fig. 3C). Interferon-γ 
levels were not significantly different after ISS administration 
(P>0.05; Fig. 3C).
DISCUSSION
The present study demonstrated that mDC are potent APC 
that orchestrate the asthmatic reaction, and that pDC do not 
elicit an asthmatic reaction in a mouse model, whether treated 
with ISS or not.
pDC have a plasma cell-like morphology and were recently 
identified in lymphoid tissues as CD11c
+B220
+Gr-1
+CD45Rb
high-
CD11b
- cells.
11,12 Although the mechanism and regulation of 
pDC development is not clearly understood, pDC can be grown 
with the aid of the Flt3 ligand, which is the only known cytokine 
to promote pDC development; its effect has been confirmed in 
human in vivo studies. We used Flt3 ligand to culture pDC in 
vitro and isolated them using anti-CD11c and anti-B220 MACS 
antibodies. Although the isolated pDC were not 100% pure, 
their purity was about 94%. Thus, these CD11c+B220+ pDC well 
represent the general pDC population.
We first confirmed the capacity of mDC to elicit an asthmatic 
reaction using increasing numbers of mDC pulsed with OVA. 
Intratracheally administered mDC induced asthma in an mDC 
number-dependent manner. As the numbers of mDC adminis-
tered intratracheally increased, airway hyperresponsiveness, 
eosinophil counts, and Th2 cytokines in BAL also increased, 
suggesting an important role of mDC in initiating and orches-
trating asthmatic reactions.
In contrast to mDC, pDC have been reported to be only poor-
ly phagocytic and pinocytic.
13 pDC can present endogenous vi-
ral antigen and prime CD8 T cell responses to endogenous an-
tigens or peptides, but not to exogenous antigens,
14 implying 
greater specialization in presenting viral or endogenous anti-
gens. Exogenous OVA antigen can be taken up by both pDC and 
mDC; however, only mDC can induce the generation of effec-
tor T cells,
15 which is consistent with our data that pDC pulsed 
with OVA did not induce asthma in mice. A previous study re-
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ported that adoptive transfer of pDC before sensitization inhib-
ited asthmatic reactions, and pDC suppressed the generation 
of effector T cells.
15 We also used a mixture of pDC and mDC, 
expecting to see inhibition of asthmatic reactions by pDC. How-
ever, no such inhibition was detected (data not shown). The 
variation in injection time may have caused this difference.
We showed that ISS-treated mDC inhibited asthmatic reac-
tions (Fig. 2), implying that ISS may alter the ability of mDC to 
inhibit Th2 response. ISS-treated mDC are known to change 
from a pro- to an anti-inflammatory phenotype in the mouse 
colitis model,
16 implying that such a change in DC phenotype 
caused by ISS may have occurred in this case. The anti-asth-
matic effect of ISS has been reported many times, and here we 
demonstrated that mDC pulsed with ISS changed the cytokine 
milieu of the lungs (Fig. 2D). Additionally, ISS significantly in-
hibited migration of DC to the lungs, suggesting an anti-asth-
matic mechanism of ISS (Fig. 3). Although the population of 
CD11c+B220+ cells also decreased from 1.08% to 0.69% after 
ISS administration, this proportion of CD11c+B220+ cells is so 
small that the meaning of these data should be evaluated fur-
ther.
In conclusion, we found that pDC played only a limited role 
in priming T cells in the mouse model of asthma using OVA an-
tigen; however, mDC played a major role in the induction of 
asthma. In addition, ISS had inhibitory effects on DC, inducing 
asthma by inhibiting migration of DC to the lungs.
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